<?xml version='1.0' encoding='utf-8'?>
<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
  <article xml:lang="en" article-type="research-article" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">660</journal-id>
        <journal-id journal-id-type="pmc-domain">jco</journal-id>
        <journal-id journal-id-type="publisher-id">JCO</journal-id>
        <journal-title-group>
          <journal-title>Journal of Clinical Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0732-183X</issn>
        <issn pub-type="epub">1527-7755</issn>
        <publisher>
          <publisher-name>American Society of Clinical Oncology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8824393</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8824393.1</article-id>
        <article-id pub-id-type="pmcaid">8824393</article-id>
        <article-id pub-id-type="pmcaiid">8824393</article-id>
        <article-id pub-id-type="pmid">34890214</article-id>
        <article-id pub-id-type="doi">10.1200/JCO.21.00896</article-id>
        <article-id pub-id-type="publisher-id">JCO.21.00896</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>ORIGINAL REPORTS</subject>
            <subj-group>
              <subject>Breast Cancer</subject>
            </subj-group>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6380-5944</contrib-id>
            <name name-style="western">
              <surname>Krop</surname>
              <given-names initials="IE">Ian E.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff1" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="cor1" ref-type="corresp" />
            <xref rid="con1" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5396-6533</contrib-id>
            <name name-style="western">
              <surname>Im</surname>
              <given-names initials="SA">Seock-Ah</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff2" ref-type="aff">
              <sup>2</sup>
            </xref>
            <xref rid="con2" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6021-667X</contrib-id>
            <name name-style="western">
              <surname>Barrios</surname>
              <given-names initials="C">Carlos</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff3" ref-type="aff">
              <sup>3</sup>
            </xref>
            <xref rid="con3" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4293-9748</contrib-id>
            <name name-style="western">
              <surname>Bonnefoi</surname>
              <given-names initials="H">Hervé</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff4" ref-type="aff">
              <sup>4</sup>
            </xref>
            <xref rid="con4" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3837-9928</contrib-id>
            <name name-style="western">
              <surname>Gralow</surname>
              <given-names initials="J">Julie</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff5" ref-type="aff">
              <sup>5</sup>
            </xref>
            <xref rid="con5" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1488-9958</contrib-id>
            <name name-style="western">
              <surname>Toi</surname>
              <given-names initials="M">Masakazu</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff6" ref-type="aff">
              <sup>6</sup>
            </xref>
            <xref rid="con6" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ellis</surname>
              <given-names initials="PA">Paul A.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff7" ref-type="aff">
              <sup>7</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2372-9625</contrib-id>
            <name name-style="western">
              <surname>Gianni</surname>
              <given-names initials="L">Luca</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff8" ref-type="aff">
              <sup>8</sup>
            </xref>
            <xref rid="con7" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1320-3830</contrib-id>
            <name name-style="western">
              <surname>Swain</surname>
              <given-names initials="SM">Sandra M.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff9" ref-type="aff">
              <sup>9</sup>
            </xref>
            <xref rid="con8" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Im</surname>
              <given-names initials="YH">Young-Hyuck</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff10" ref-type="aff">
              <sup>10</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9009-1572</contrib-id>
            <name name-style="western">
              <surname>De Laurentiis</surname>
              <given-names initials="M">Michelino</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff11" ref-type="aff">
              <sup>11</sup>
            </xref>
            <xref rid="con9" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7706-8191</contrib-id>
            <name name-style="western">
              <surname>Nowecki</surname>
              <given-names initials="Z">Zbigniew</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff12" ref-type="aff">
              <sup>12</sup>
            </xref>
            <xref rid="con10" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6557-211X</contrib-id>
            <name name-style="western">
              <surname>Huang</surname>
              <given-names initials="CS">Chiun-Sheng</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff13" ref-type="aff">
              <sup>13</sup>
            </xref>
            <xref rid="con11" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1300-1905</contrib-id>
            <name name-style="western">
              <surname>Fehrenbacher</surname>
              <given-names initials="L">Louis</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff14" ref-type="aff">
              <sup>14</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ito</surname>
              <given-names initials="Y">Yoshinori</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff15" ref-type="aff">
              <sup>15</sup>
            </xref>
            <xref rid="con12" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Shah</surname>
              <given-names initials="J">Jigna</given-names>
            </name>
            <degrees>DPharm</degrees>
            <xref rid="aff16" ref-type="aff">
              <sup>16</sup>
            </xref>
            <xref rid="con13" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Boulet</surname>
              <given-names initials="T">Thomas</given-names>
            </name>
            <degrees>MS</degrees>
            <xref rid="aff17" ref-type="aff">
              <sup>17</sup>
            </xref>
            <xref rid="con14" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Liu</surname>
              <given-names initials="H">Haiying</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff16" ref-type="aff">
              <sup>16</sup>
            </xref>
            <xref rid="con15" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Macharia</surname>
              <given-names initials="H">Harrison</given-names>
            </name>
            <degrees>MSc</degrees>
            <xref rid="aff17" ref-type="aff">
              <sup>17</sup>
            </xref>
            <xref rid="con16" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Trask</surname>
              <given-names initials="P">Peter</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="aff16" ref-type="aff">
              <sup>16</sup>
            </xref>
            <xref rid="con17" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Song</surname>
              <given-names initials="C">Chunyan</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff16" ref-type="aff">
              <sup>16</sup>
            </xref>
            <xref rid="con18" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8819-1723</contrib-id>
            <name name-style="western">
              <surname>Winer</surname>
              <given-names initials="EP">Eric P.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff1" ref-type="aff">
              <sup>1</sup>
            </xref>
            <xref rid="con19" ref-type="fn" />
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9744-7372</contrib-id>
            <name name-style="western">
              <surname>Harbeck</surname>
              <given-names initials="N">Nadia</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff18" ref-type="aff">
              <sup>18</sup>
            </xref>
            <xref rid="con20" ref-type="fn" />
          </contrib>
          <aff id="aff1">
            <label>
              <sup>1</sup>
            </label>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</aff>
          <aff id="aff2">
            <label>
              <sup>2</sup>
            </label>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea</aff>
          <aff id="aff3">
            <label>
              <sup>3</sup>
            </label>Oncology Research Unit, Oncoclínicas, HSL, PUCRS, Porto Alegre, <country>Brazil</country>
          </aff>
          <aff id="aff4">
            <label>
              <sup>4</sup>
            </label>Institut Bergonié Unicancer and Bordeaux University, Bordeaux, <country>France</country>
          </aff>
          <aff id="aff5">
            <label>
              <sup>5</sup>
            </label>University of Washington, Seattle, WA</aff>
          <aff id="aff6">
            <label>
              <sup>6</sup>
            </label>Graduate School of Medicine, Kyoto University, Kyoto, <country>Japan</country>
          </aff>
          <aff id="aff7">
            <label>
              <sup>7</sup>
            </label>Guy's Hospital and Sarah Cannon Research Institute, London, <country>UK</country>
          </aff>
          <aff id="aff8">
            <label>
              <sup>8</sup>
            </label>Michelangelo Foundation, Milan, <country>Italy</country>
          </aff>
          <aff id="aff9">
            <label>
              <sup>9</sup>
            </label>Georgetown University Medical Center and MedStar Health, Washington, DC</aff>
          <aff id="aff10">
            <label>
              <sup>10</sup>
            </label>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</aff>
          <aff id="aff11">
            <label>
              <sup>11</sup>
            </label>IRCCS Instituto Nazionale Tumori Fondazione Pascale, Naples, <country>Italy</country>
          </aff>
          <aff id="aff12">
            <label>
              <sup>12</sup>
            </label>Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, <country>Poland</country>
          </aff>
          <aff id="aff13">
            <label>
              <sup>13</sup>
            </label>National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan</aff>
          <aff id="aff14">
            <label>
              <sup>14</sup>
            </label>Kaiser Permanente, Northern California, Vallejo, CA</aff>
          <aff id="aff15">
            <label>
              <sup>15</sup>
            </label>Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, <country>Japan</country>
          </aff>
          <aff id="aff16">
            <label>
              <sup>16</sup>
            </label>Genentech, Inc, South San Francisco, CA</aff>
          <aff id="aff17">
            <label>
              <sup>17</sup>
            </label>F. Hoffmann-La Roche, Basel, <country>Switzerland</country>
          </aff>
          <aff id="aff18">
            <label>
              <sup>18</sup>
            </label>Breast Center, Dept. OB&amp;GYN, LMU University Hospital, Munich, <country>Germany</country>
          </aff>
        </contrib-group>
        <author-notes>
          <corresp id="cor1">Ian E. Krop, MD, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215; e-mail: <email>Ian_Krop@dfci.harvard.edu</email>.</corresp>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>10</day>
          <month>2</month>
          <year>2022</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>10</day>
          <month>12</month>
          <year>2021</year>
        </pub-date>
        <volume>40</volume>
        <issue>5</issue>
        <issue-id pub-id-type="pmc-issue-id">400549</issue-id>
        <fpage>438</fpage>
        <lpage>448</lpage>
        <self-uri content-type="pmc-pdf" ns0:href="jco-40-438.pdf" />
        <self-uri ns0:href="jco-40-438.pdf" />
        <abstract>
          <title>PURPOSE</title>
          <p>We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1).</p>
          <sec>
            <title>METHODS</title>
            <p>The phase III KAITLIN study (<ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT01966471" ext-link-type="uri">NCT01966471</ext-link>) included adults with excised HER2-positive EBC (node-positive or node-negative, hormone receptor–negative, and tumor &gt; 2.0 cm). Postsurgery, patients were randomly assigned 1:1 to anthracycline-based chemotherapy (three-four cycles) and then 18 cycles of T-DM1 plus pertuzumab (AC-KP) or taxane (three-four cycles) plus trastuzumab plus pertuzumab (AC-THP). Adjuvant radiotherapy/endocrine therapy was permitted. Coprimary end points were invasive disease-free survival (IDFS) in the intention-to-treat node-positive and overall populations with hierarchical testing.</p>
          </sec>
          <sec>
            <title>RESULTS</title>
            <p>The median follow-up was 57.1 months (interquartile range, 52.1-60.1 months) for AC-THP (n = 918) and 57.0 months (interquartile range, 52.1-59.8 months) for AC-KP (n = 928). There was no significant IDFS difference between arms in the node-positive (n = 1,658; stratified hazard ratio [HR], 0.97; 95% CI, 0.71 to 1.32) or overall population (n = 1846; stratified HR, 0.98; 95% CI, 0.72 to 1.32). In the overall population, the three-year IDFS was 94.2% (95% CI, 92.7 to 95.8) for AC-THP and 93.1% (95% CI, 91.4 to 94.7) for AC-KP. Treatment completion rates (ie, 18 cycles) were 88.4% for AC-THP and 65.0% for AC-KP (difference driven by T-DM1 discontinuation because of laboratory abnormalities [12.5%]). Similar rates of grade ≥ 3 (55.4% <italic toggle="yes">v</italic> 51.8%) and serious adverse events (23.3% <italic toggle="yes">v</italic> 21.4%) occurred with AC-THP and AC-KP, respectively. KP decreased clinically meaningful deterioration in global health status versus THP (stratified HR, 0.71; 95% CI, 0.62 to 0.80).</p>
          </sec>
          <sec>
            <title>CONCLUSION</title>
            <p>The primary end point was not met. Both arms achieved favorable IDFS. Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.</p>
          </sec>
        </abstract>
        <counts>
          <fig-count count="8" />
          <table-count count="2" />
          <equation-count count="0" />
          <ref-count count="31" />
          <page-count count="0" />
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-license-ref</meta-name>
            <meta-value>CC BY-NC-ND</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>OPEN-ACCESS</meta-name>
            <meta-value>TRUE</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec sec-type="introduction">
        <title>INTRODUCTION</title>
        <p>The standard of care for adjuvant treatment of human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (EBC) is chemotherapy plus 1 year of HER2-directed therapy.<sup>
            <xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref>
          </sup> However, high-risk populations (node-positive and/or tumors &gt; 2 cm) receiving trastuzumab have 5-year disease-free survival rates of &lt; 85%.<sup>
            <xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b4" ref-type="bibr">4</xref>
          </sup> In APHINITY,<sup>
            <xref rid="b5" ref-type="bibr">5</xref>
          </sup> adjuvant chemotherapy and dual HER2 targeting with pertuzumab plus trastuzumab improved invasive disease-free survival (IDFS) compared with trastuzumab alone in the intention-to-treat (ITT) population and more markedly in patients with node-positive disease: the 6-year IDFS was 88% with dual targeting versus 83% with trastuzumab.<sup>
            <xref rid="b6" ref-type="bibr">6</xref>
          </sup> Another challenge of current EBC treatment is systemic chemotherapy-associated toxicity. Taxanes are associated with well-characterized toxicities, including neutropenia, febrile neutropenia, alopecia, neuropathy, myalgia, and arthralgia.<sup>
            <xref rid="b7" ref-type="bibr">7</xref>-<xref rid="b10" ref-type="bibr">10</xref>
          </sup>
        </p>
        <boxed-text id="B1" position="anchor" orientation="portrait">
          <sec sec-type="context-box">
            <title>CONTEXT</title>
            <p>
              <list list-type="simple">
                <list-item>
                  <p>
                    <bold>Key Objective</bold>
                  </p>
                </list-item>
                <list-item>
                  <p>Current treatments for high-risk human epidermal growth factor receptor 2 (HER2)–positive breast cancer have limitations in terms of efficacy and tolerability, the latter primarily because of toxicities associated with chemotherapy. Improved outcomes have been shown with the addition of pertuzumab to trastuzumab and chemotherapy in metastatic and neoadjuvant settings. Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate composed of the cytotoxic agent DM1 linked to trastuzumab, which could provide an alternative to taxane-plus-trastuzumab to improve safety and efficacy, when combined with pertuzumab.</p>
                </list-item>
                <list-item>
                  <p>
                    <bold>Knowledge Generated</bold>
                  </p>
                </list-item>
                <list-item>
                  <p>In high-risk HER2-positive breast cancer, replacing the combination of taxane-plus-trastuzumab and pertuzumab with T-DM1 and pertuzumab (after surgery and anthracycline chemotherapy) did not yield a clinically meaningful improvement in efficacy and demonstrated a safety profile consistent with previous experience.</p>
                </list-item>
                <list-item>
                  <p>
                    <bold>Relevance</bold>
                  </p>
                </list-item>
                <list-item>
                  <p>The approach for management of high-risk HER2-positive breast cancer remains initial treatment with neoadjuvant trastuzumab/pertuzumab and chemotherapy and escalation to adjuvant T-DM1 for residual disease.</p>
                </list-item>
              </list>
            </p>
          </sec>
        </boxed-text>
        <p>Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate composed of the cytotoxic agent DM1 covalently linked to trastuzumab.<sup>
            <xref rid="b11" ref-type="bibr">11</xref>
          </sup> T-DM1 retains the HER2-targeted effects of trastuzumab and provides targeted delivery of emtansine (MCC-DM1).<sup>
            <xref rid="b12" ref-type="bibr">12</xref>
          </sup> In the metastatic setting, single-agent T-DM1 is effective, and is the standard of care, in patients with cancer resistant to trastuzumab plus a taxane.<sup>
            <xref rid="b13" ref-type="bibr">13</xref>-<xref rid="b16" ref-type="bibr">16</xref>
          </sup>
        </p>
        <p>In KAITLIN, we aimed to improve efficacy and reduce toxicity of adjuvant chemotherapy in HER2-positive, high-risk EBC by replacing taxane-plus-trastuzumab with T-DM1 after anthracycline chemotherapy. On the basis of preclinical data showing synergistic antitumor activity with pertuzumab-plus-T-DM1,<sup>
            <xref rid="b17" ref-type="bibr">17</xref>
          </sup> clinical data showing safety and activity of the combination,<sup>
            <xref rid="b18" ref-type="bibr">18</xref>
          </sup> and improved outcomes with the addition of pertuzumab to trastuzumab in metastatic<sup>
            <xref rid="b19" ref-type="bibr">19</xref>
          </sup> and neoadjuvant settings,<sup>
            <xref rid="b20" ref-type="bibr">20</xref>,<xref rid="b21" ref-type="bibr">21</xref>
          </sup> KAITLIN was designed with each arm receiving pertuzumab. After KAITLIN was underway, data from the MARIANNE trial, testing the T-DM1-plus-pertuzumab combination in previously untreated metastatic disease, became available. T-DM1-plus-pertuzumab demonstrated similar efficacy, but not superiority, and better tolerability than trastuzumab-plus-taxane.<sup>
            <xref rid="b22" ref-type="bibr">22</xref>
          </sup> Because the experimental arm in KAITLIN (anthracycline-plus-T-DM1-plus-pertuzumab) was expected to demonstrate a risk-benefit profile at least equivalent to the adjuvant standard of care at that time (anthracycline-plus-taxane-plus-trastuzumab) and because the question of whether it could be similar or superior to standard adjuvant regimens remained important, the trial continued. Here, we report the primary results of KAITLIN.</p>
      </sec>
      <sec sec-type="methods">
        <title>METHODS</title>
        <sec sec-type="subjects">
          <title>Study Design and Patients</title>
          <p>KAITLIN (<ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT01966471" ext-link-type="uri">NCT01966471</ext-link>) is a randomized, multinational, open-label study conducted in 288 centers in 36 countries (Data Supplement, online only). Eligible patients had newly diagnosed, HER2-positive, nonmetastatic, histologically confirmed, operable primary invasive breast carcinoma. Eligible patients had node-positive disease (pN ≥ 1), with any tumor size except T0 and any hormone receptor status, or node-negative disease (pN0) with the pathologic tumor size &gt; 2.0 cm by local assessment and negative for estrogen receptor (ER) and progesterone receptor (PgR). Hormone receptor status and HER2 status were centrally determined. HER2 status was measured using the PATHWAY HER2 4B5 Immunohistochemistry Assay (Ventana Medical Systems, Inc, Oro Valley, AZ) and the INFORM HER2 Dual in Situ Hybridization Assay (Ventana Medical Systems, Inc, Oro Valley, AZ). HER2-positive status was defined as an immunohistochemistry (IHC) score of 3+ and/or an in situ hybridization <italic toggle="yes">HER2:</italic>chromosome 17 ratio of ≥ 2.0. Patients had to have a baseline left ventricular ejection fraction (LVEF) of ≥ 55% (by echocardiogram or multigated acquisition scans). Complete eligibility criteria are listed in the Data Supplement.</p>
          <p>The Protocol (online only) was approved by the independent ethics committees and/or institutional review boards at each site. The trial was performed in accordance with the Declaration of Helsinki and guidelines for Good Clinical Practice. All participants provided written informed consent. The trial was overseen by a steering committee and an independent data monitoring committee. An independent clinical events committee adjudicated prespecified safety events of interest (cardiac and hepatic dysfunction events) in a blinded fashion.</p>
        </sec>
        <sec sec-type="methods">
          <title>Procedures</title>
          <p>Patients were randomly assigned 1:1 within 9 weeks of definitive breast surgery to anthracycline chemotherapy followed by trastuzumab and a taxane plus pertuzumab (AC-THP) or anthracycline chemotherapy followed by T-DM1 plus pertuzumab (AC-KP; Appendix Fig A<xref rid="figA1" ref-type="fig">1</xref>, online only). Random assignment was performed according to a permuted block scheme, stratified by region (United States or Canada, Western Europe or Australia or New Zealand, Asia, and rest of world), nodal status (0, 1-3, or ≥ 4 positive nodes), hormone receptor status (ER- and/or PgR-positive or both ER- and PgR-negative), and anthracycline type (doxorubicin or epirubicin).</p>
          <p>Anthracycline and taxane regimens were chosen by the investigator before random assignment and according to protocol-specified regimens (Data Supplement). T-DM1 was dosed at 3.6 mg/kg once every 3 weeks. Trastuzumab was dosed at 6 mg/kg once every 3 weeks after an 8-mg/kg loading dose and started concurrently with the taxane. Pertuzumab was dosed at 420 mg once every 3 weeks after an 840-mg loading dose and administered concurrently with T-DM1 or trastuzumab-plus-taxane. An interval of ≥ 3 weeks from the last dose of anthracycline to initiation of HER2-targeted therapy was required. After the taxane-concurrent phase in the trastuzumab-containing arm, trastuzumab-plus-pertuzumab was continued for ≥ 1 year. In the T-DM1–containing arm, T-DM1-plus-pertuzumab was continued for ≥ 1 year. For toxicities, dose delays and/or reductions were permitted for anthracyclines, taxanes, and T-DM1; only dose delays were permitted for trastuzumab and pertuzumab. For patients discontinuing T-DM1 because of toxicity, switching to trastuzumab was recommended to complete ≥ 1 year of HER2-targeted therapy. Adjuvant radiotherapy and/or hormonal therapy was given as clinically indicated at the end of taxane chemotherapy or after four cycles of T-DM1 during HER2-targeted therapy.</p>
        </sec>
        <sec>
          <title>Outcomes</title>
          <p>The coprimary efficacy end points were IDFS in the node-positive subpopulation and IDFS in the overall population. IDFS was defined as the time from random assignment until the date of first occurrence of one of the following: ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral or ipsilateral second primary invasive breast cancer, distant recurrence, or death because of any cause.</p>
          <p>Secondary efficacy end points in the node-positive subpopulation and overall population were IDFS plus second primary nonbreast cancer, disease-free survival (time between random assignment and first occurrence of an IDFS event, second primary nonbreast cancer event, and contralateral or ipsilateral ductal carcinoma in situ), distant recurrence-free interval (time between random assignment and first occurrence of distant breast cancer recurrence), and overall survival (OS—time from random assignment to death because of any cause). Adverse events (AEs) were coded according to the Medical Dictionary for Regulatory Activities and graded according to the National Cancer Institute Common Terminology Criteria for AEs v4.0. The primary adjudicated cardiac safety end point comprised severe heart failure (New York Heart Association [NYHA] classification III or IV) and significant LVEF decline (decline of ≥ 10 percentage points to a value &lt; 50%) or cardiac death. Secondary cardiac event end points were symptomatic left ventricular systolic dysfunction (LVSD; NYHA II) with significant LVEF decline and asymptomatic LVSD. Patient-reported outcomes (PROs) included the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core 30 (QLQ-C30) and the modified EORTC Breast Cancer module (QLQ-BR23). Clinically meaningful deterioration in global health status/QOL was defined as a decrease in the baseline score of ≥ 10 points.<sup>
              <xref rid="b23" ref-type="bibr">23</xref>
            </sup> Deterioration in function and symptoms was defined by minimally important differences.<sup>
              <xref rid="b24" ref-type="bibr">24</xref>
            </sup>
          </p>
        </sec>
        <sec>
          <title>Statistical Analysis</title>
          <p>To achieve 82.5% power in the overall population, approximately 171 IDFS events were required, and 160 events were needed to achieve 80% power in the node-positive subpopulation to detect a hazard ratio (HR) of 0.64, at a two-sided significance level of 5% (log-rank test). Approximately 1,850 and 1,665 patients were required for enrollment in the overall population and node-positive subpopulation, respectively. After the phase III MARIANNE trial showed noninferior (but not superior) progression-free survival with T-DM1, with or without pertuzumab, compared with trastuzumab-and-a-taxane in metastatic disease,<sup>
              <xref rid="b22" ref-type="bibr">22</xref>
            </sup> it was assumed that the likelihood of the study meeting its primary efficacy end point for superiority had decreased, and hence, the sample size was reduced from 2,500 to approximately 1,850 to decrease the risk of exposing more patients to a potentially suboptimal treatment. Because this is a time-to-event end point and as such statistical power is dependent on the number of events, not the sample size, the reduction in sample size did not reduce statistical power, but potentially increased the time to attain the prespecified number of events for the primary end point analysis.</p>
          <p>Efficacy was evaluated on an ITT basis. The primary end point, IDFS, was compared between treatment arms with the log-rank test, stratified by protocol-defined stratification factors, excluding region—because some strata could have few patients, limiting statistical power. Data from patients without an event at the time of data analysis were censored on the date they were last known to be alive and event-free. The Cox proportional hazards model was used to estimate HRs between treatment arms and corresponding 95% CIs for time-to-event end points. The Kaplan-Meier approach was used to estimate 3- and 5-year event rates and corresponding 95% CIs for time-to-event end points. A hierarchical testing procedure was used to control the overall study type I error rate at 5%: (1) IDFS in the node-positive subpopulation, (2) IDFS in the overall population, (3) OS in the node-positive subpopulation, and (4) OS in the overall population. An interim analysis of IDFS was performed after approximately 75% of IDFS events were observed in the overall protocol-defined population and node-positive subpopulation.</p>
          <p>Patients with baseline and ≥ 1 post-treatment assessment were included in PRO analyses. Time to clinically meaningful deterioration in PRO scales, derived using cycle 1 day 1 of HER2-targeted treatment as the reference timepoint, was analyzed using the same time-to-event methods used to analyze IDFS.</p>
        </sec>
      </sec>
      <sec sec-type="results">
        <title>RESULTS</title>
        <p>Between January 2014 and June 2015, 1,846 patients were enrolled (n = 918, AC-THP; n = 928, AC-KP [Fig <xref rid="fig1" ref-type="fig">1</xref>]). Of these, 1,658 (89.8%) comprised the node-positive subpopulation (n = 826, AC-THP; n = 832, AC-KP). A total of 167 patients switched from T-DM1 to trastuzumab (Data Supplement). The median follow-up was 57.1 months (interquartile range, 52.1-60.1 months) in the AC-THP and 57.0 months (interquartile range, 52.1-59.8 months) in the AC-KP arm. Baseline characteristics were balanced between groups (Table <xref rid="tbl1" ref-type="table">1</xref>).</p>
        <fig position="float" id="fig1" fig-type="figure" orientation="portrait">
          <label>FIG 1.</label>
          <caption>
            <p>CONSORT diagram. <sup>a</sup>Includes the 16 patients in the AC-THP arm who received AC but not THP and the 13 patients in the AC-KP arm who received AC but not KP. <sup>b</sup>One patient in the AC-KP arm experienced an adverse event that first led to study discontinuation and eventually to death. This patient is counted both as discontinued study because of death and discontinued study because of other. AC, anthracycline chemotherapy; AC-KP, anthracycline chemotherapy followed by trastuzumab emtansine plus pertuzumab; AC-THP, anthracycline chemotherapy followed by a taxane plus trastuzumab plus pertuzumab; BC, breast cancer; HER2+, human epidermal growth factor receptor 2–positive; HP, trastuzumab plus pertuzumab; ITT, intention to treat; KP, trastuzumab emtansine plus pertuzumab.</p>
          </caption>
          <graphic position="float" orientation="portrait" ns0:href="jco-40-438-g001.jpg" />
        </fig>
        <table-wrap position="float" id="tbl1" orientation="portrait">
          <label>TABLE 1.</label>
          <caption>
            <p>Baseline Characteristics</p>
          </caption>
          <graphic position="float" orientation="portrait" ns0:href="jco-40-438-g002.jpg" />
        </table-wrap>
        <sec>
          <title>Efficacy</title>
          <p>As of November 2019, among the ITT lymph node–positive subpopulation, 82 (9.9%) IDFS events had occurred in the AC-THP arm and 80 (9.6%) had occurred in the AC-KP arm. Treatment with AC-KP did not reduce the risk of an IDFS event compared with AC-THP in the node-positive subpopulation (stratified HR, 0.97; 95% CI, 0.71 to 1.32; <italic toggle="yes">P</italic> = .83; Fig <xref rid="fig2" ref-type="fig">2</xref>A), so hierarchical testing was stopped. In this subpopulation, 3-year IDFS rates were 94.1% (95% CI, 92.5 to 95.7) with AC-THP and 92.8% (95% CI, 91.0 to 94.5) with AC-KP. Sites of recurrence were similar in each arm (Data Supplement). Among the ITT overall population, 88 (9.6%) IDFS events occurred in the AC-THP arm and 86 (9.3%) occurred in the AC-KP arm. AC-KP did not reduce the risk of an IDFS event compared with AC-THP (stratified HR, 0.98; 95% CI, 0.72 to 1.32; Fig <xref rid="fig2" ref-type="fig">2</xref>B). Three-year IDFS rates were 94.2% (95% CI, 92.7 to 95.8) with AC-THP and 93.1% (95% CI, 91.4 to 94.7) with AC-KP. Sites of recurrence were similar in each arm (Data Supplement). In prespecified exploratory subgroup analysis, IDFS was consistently similar between arms across subgroups, except for a modest advantage with AC-THP versus AC-KP in the subgroup undergoing breast-conserving surgery (Fig <xref rid="fig3" ref-type="fig">3</xref>). Rates of secondary nonprimary breast cancer, disease-free survival, and distant recurrence-free interval were similar between treatment arms (Data Supplement). OS data were immature with event rates of 3.6% and 4.7% in patients receiving AC-THP and AC-KP, respectively.</p>
          <fig position="float" id="fig2" fig-type="figure" orientation="portrait">
            <label>FIG 2.</label>
            <caption>
              <p>Kaplan-Meier plot of IDFS in the intention-to-treat lymph node–positive (A) subpopulation and (B) overall population. Stratified Cox regression and stratified log-rank test were used to assess HR (along with corresponding 95% CI) and <italic toggle="yes">P</italic> value. Stratification was based on the random assignment stratification factors: nodal status (0 positive nodes; 1-3 positive nodes; ≥ 4 positive nodes), centrally assessed hormone receptor status (ER- and/or PgR-positive or both ER- and PgR-negative), and type of planned anthracycline (doxorubicin or epirubicin). AC-KP, anthracycline chemotherapy followed by trastuzumab emtansine plus pertuzumab; AC-THP, anthracycline chemotherapy followed by a taxane plus trastuzumab plus pertuzumab; ER, estrogen receptor; HR, hazard ratio; IDFS, invasive disease-free survival; PgR, progesterone receptor.</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-40-438-g003.jpg" />
          </fig>
          <fig position="float" id="fig3" fig-type="figure" orientation="portrait">
            <label>FIG 3.</label>
            <caption>
              <p>Subgroup analysis of IDFS. Forest plot showing comparison of AC-KP versus AC-THP in subgroups of the overall intention-to-treat population. Unstratified Cox proportional hazard regression was used to estimate HR and CI in each covariate subgroup. AC-KP, anthracycline chemotherapy followed by trastuzumab emtansine plus pertuzumab; AC-THP, anthracycline chemotherapy followed by a taxane plus trastuzumab plus pertuzumab; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IDFS, invasive disease-free survival; NE, not estimable; PgR, progesterone receptor.</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-40-438-g004.jpg" />
          </fig>
        </sec>
        <sec>
          <title>Safety</title>
          <p>The safety population comprised 1838 patients who received ≥ 1 dose of study treatment (Table <xref rid="tbl2" ref-type="table">2</xref>). All 18 cycles of trastuzumab or T-DM1 were completed by 819 (88.4%) patients receiving AC-THP and 593 (65.0%) receiving AC-KP (Data Supplement). Including patients who switched from T-DM1 to trastuzumab, 743 (81.5%) in the AC-KP arm completed HER2-targeted therapy. Of patients in the AC-THP arm, 167 (18.0%) had a taxane dose reduction. A total of 281 (30.8%) patients receiving AC-KP had a T-DM1 dose reduction (one-level, 172 [18.9%]; two-level, 109 [12.0%]; Data Supplement). A similar proportion of patients in each arm completed all 18 cycles of pertuzumab (Data Supplement).</p>
          <table-wrap position="float" id="tbl2" orientation="portrait">
            <label>TABLE 2.</label>
            <caption>
              <p>AEs</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-40-438-g005.jpg" />
          </table-wrap>
          <p>The rates of grade ≥ 3 AEs and serious AEs were similar between treatment arms (Table <xref rid="tbl2" ref-type="table">2</xref>). AEs leading to discontinuation of trastuzumab or T-DM1 occurred in 4.0% of patients receiving AC-THP and 26.8% receiving AC-KP. AEs leading to discontinuation of taxane occurred in 6.7% of AC-THP patients. The most common AE leading to discontinuation of trastuzumab was decreased ejection fraction (13 [1.4%] patients). AEs leading to discontinuation of T-DM1 were largely laboratory abnormalities (114 of 244 [47%]), most commonly increased bilirubin (49 [5.4%] patients) and decreased platelet count (30 [3.3%]). Deaths related to an AE occurred in two (0.2%) patients receiving AC-THP (pneumonia and hydrothorax [n = 1] and uterine leiomyosarcoma [n = 1]) and in five (0.5%) patients receiving AC-KP (pneumonia [n = 2], colon neoplasm [n = 1], depression leading to suicide [n = 1], and metabolic acidosis [n = 1]). None was deemed related to study treatment by the investigator.</p>
          <p>Adjudicated primary cardiac events occurred in 1.1% of patients receiving AC-THP and 0.4% receiving AC-KP; no cardiac deaths occurred (Data Supplement). A secondary cardiac event was observed in 5.7% of patients receiving AC-THP and 2.6% receiving AC-KP. Nodular regenerative hyperplasia occurred in four (0.4%) patients receiving AC-KP—two grade 2, one grade 3, and one not reported as an AE (so severity not assessed). Of the three cases reported as AEs, two resolved. Of AEs known to occur with either treatment regimen, the most common AEs occurring in more patients receiving AC-KP versus AC-THP were any-grade hepatotoxicity (47.6% <italic toggle="yes">v</italic> 15.6%), any-grade thrombocytopenia (32.3% <italic toggle="yes">v</italic> 4.0%), and any-grade hemorrhage (45.9% <italic toggle="yes">v</italic> 25.9%). Any-grade pulmonary toxicity occurred in 2.2% of patients receiving AC-THP and 3.3% receiving AC-KP, with grade ≥ 3 events occurring in one patient in each arm. Radiation-related pneumonitis occurred in 1.4% of patients receiving AC-THP and 2.3% receiving AC-KP.</p>
        </sec>
        <sec>
          <title>PROs</title>
          <p>PRO completion rates were similar between arms (&gt; 85% of evaluable patients across all assessment timepoints; Data Supplement). Baseline scores on the QLQ-C30 and QLQ-BR23 reflected moderate-to-high levels of functioning and overall QOL and low levels of disease- and treatment-related symptoms (Appendix Fig A<xref rid="figA2" ref-type="fig">2</xref>, online only). During the anthracycline treatment period, there was a consistent pattern of deterioration across subscales and treatment arms (Appendix Fig A<xref rid="figA3" ref-type="fig">3</xref>, online only). As expected, the adjusted mean scores for the QLQ-C30 and QLQ-BR23 function scales (Data Supplement) and the QLQ-C30 and QLQ-BR23 symptom scales were similar between arms at cycle 1 of the HER2-targeted treatment period, with the exception of arm symptoms (adjusted mean AC-THP, 18.0; AC-KP, 15.9; difference in adjusted means, –2.1 [95% CI, –3.9 to –0.3]; data not shown), a difference that was not clinically meaningful. From the start of HER2-targeted therapy, deterioration of functioning stopped in the AC-KP arm, whereas it continued during the taxane phase in the AC-THP arm. When taxane was stopped, functioning improved in the AC-THP arm and became similar to the AC-KP arm thereafter. The risk of experiencing a clinically meaningful deterioration in global health status from the start of HER2-targeted therapy was reduced by 29% in the AC-KP versus AC-THP arm (stratified HR, 0.71; 95% CI, 0.62 to 0.80), with the majority of the deterioration occurring during the first five cycles of HER2-targeted therapy (Fig <xref rid="fig4" ref-type="fig">4</xref> and Data Supplement). Similar results were observed in physical and role functioning (Appendix Fig A<xref rid="figA4" ref-type="fig">4</xref>, online only). Mean change from baseline and clinically meaningful deterioration in individual symptoms of the QLQ-C30 and QLQ-BR23 are shown in the Data Supplement.</p>
          <fig position="float" id="fig4" fig-type="figure" orientation="portrait">
            <label>FIG 4.</label>
            <caption>
              <p>Time to deterioration in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 Global Health/Quality of Life Scale. Baseline defined as day 1 of HER2-targeted therapy. Stratified Cox regression was used to assess HR (along with corresponding 95% CI). Stratification was based on the random assignment stratification factors: nodal status (0 positive nodes; 1-3 positive nodes; ≥ 4 positive nodes), centrally assessed hormone receptor status (ER- and/or PgR-positive or both ER- and PgR-negative), and type of planned anthracycline (doxorubicin or epirubicin). AC-KP, anthracycline chemotherapy followed by trastuzumab emtansine plus pertuzumab; AC-THP, anthracycline chemotherapy followed by a taxane plus trastuzumab plus pertuzumab; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; NE, not estimable; PgR, progesterone receptor.</p>
            </caption>
            <graphic position="float" orientation="portrait" ns0:href="jco-40-438-g006.jpg" />
          </fig>
        </sec>
      </sec>
      <sec sec-type="discussion">
        <title>DISCUSSION</title>
        <p>Adjuvant AC-KP did not result in statistically significant or clinically meaningful improvement in IDFS compared with AC-THP in the node-positive subpopulation or overall population of patients with high-risk EBC. AC-KP and AC-THP safety profiles were consistent with previous experience. There was a lower risk of deterioration in QOL with AC-KP, likely accounted for by taxanes in the AC-THP arm, since after completion of taxane therapy, QOL returned to levels comparable with the AC-KP arm.</p>
        <p>The 3-year IDFS rates of 94.2% (AC-THP) and 93.1% (AC-KP) are notable in this high-risk population (89.8% having node-positive disease, with 34.0% having ≥ 4 positive nodes) and similar to those in patients with node-positive disease (25% with ≥ 4 positive nodes) in APHINITY.<sup>
            <xref rid="b6" ref-type="bibr">6</xref>
          </sup> These data suggest an improvement in standard of care and/or more accurate initial staging of patients since the first adjuvant trials of trastuzumab, where the 3-year IDFS was approximately 82%-88% in populations in which 68%-94% had node-positive disease, with 28%-41% having ≥ 4 positive nodes.<sup>
            <xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b25" ref-type="bibr">25</xref>
          </sup>
        </p>
        <p>Of note, the treatment approach in EBC has changed since KAITLIN was initiated. A neoadjuvant strategy is currently recommended for high-risk HER2-positive disease, and patients with residual disease after surgery now receive T-DM1 on the basis of the KATHERINE trial results.<sup>
            <xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b26" ref-type="bibr">26</xref>
          </sup> In the KATHERINE study, adjuvant T-DM1 was superior to trastuzumab in patients with residual invasive disease after a taxane–trastuzumab-containing regimen.<sup>
            <xref rid="b27" ref-type="bibr">27</xref>
          </sup> The KATHERINE data imply that there is a subset of cancers that has at least partial resistance to taxane-trastuzumab, but retains sensitivity to T-DM1. However, the observation that substituting T-DM1 for taxane-trastuzumab in KAITLIN does not improve outcomes suggests that there is also a subset of cancers resistant to T-DM1-plus-pertuzumab, for which taxane-trastuzumab-plus-pertuzumab therapy remains important. Ongoing research in samples from KAITLIN seeks to elucidate biomarkers to identify patients with cancers selectively sensitive to T-DM1 or taxanes.</p>
        <p>The lack of improved efficacy with AC-KP versus AC-THP in KAITLIN is consistent with results from KRISTINE<sup>
            <xref rid="b28" ref-type="bibr">28</xref>,<xref rid="b29" ref-type="bibr">29</xref>
          </sup> and MARIANNE,<sup>
            <xref rid="b22" ref-type="bibr">22</xref>,<xref rid="b30" ref-type="bibr">30</xref>
          </sup> two further studies evaluating KP as a chemotherapy-sparing regimen. Both failed to demonstrate that KP was superior to a taxane-plus-trastuzumab-(pertuzumab)–based regimen, particularly in patients with lower HER2 expression (HER2 IHC 2+; HER2 mRNA low) and higher HER2 heterogeneity. The KAITLIN results are consistent with other studies suggesting that longer duration of a cytotoxic agent is not beneficial in EBC.<sup>
            <xref rid="b31" ref-type="bibr">31</xref>
          </sup>
        </p>
        <p>Together, data from KAITLIN and other recent studies of HER2-directed therapy support the current tailored approach for the management of high-risk HER2-positive breast cancer: initial treatment with neoadjuvant chemotherapy and trastuzumab plus pertuzumab and escalation to adjuvant T-DM1 in those patients with residual disease. Given the favorable outcomes seen in contemporary studies of HER2-positive EBC, ongoing research is now focused on strategies to de-escalate chemotherapy while maintaining optimal HER2-targeted therapy with trastuzumab plus pertuzumab in the majority of patients (eg, CompassHER2-pCR [<ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT04266249" ext-link-type="uri">NCT04266249</ext-link>] and Decrescendo [<ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT04675827" ext-link-type="uri">NCT04675827</ext-link>]) and to escalate therapy only for the minority of patients who are at risk for recurrence despite maximal current management (eg, CompassHER2 RD [<ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT04457596" ext-link-type="uri">NCT04457596</ext-link>] and DESTINY-Breast05 [<ext-link ns0:href="https://www.clinicaltrials.gov/ct2/show/NCT04622319" ext-link-type="uri">NCT04622319</ext-link>]).</p>
      </sec>
    </body>
  </article>
</pmc-articleset>